Mylan gains rights for Zyomyx's HIV/AIDS diagnostic test

07/1/2013 | RTT News

Zyomyx has granted Mylan exclusive rights to market its Point-of-Care CD4 Diagnostic Test, a rapid diagnostic assay used in HIV/AIDS therapy that may soon be available on the market. As part of the deal, Zyomyx will receive a $12 million investment from Mylan.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN